SanBio CoSNBIF 22 Quick Ratio is 28.99 as of Jan. 2026, which is 390% above its 10-year median of 5.92. GuruFocus rates SNBIF with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, SanBio Co ranks better than 98.51% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. SanBio Co's quick ratio for the quarter that ended in Jan. 2026 was 28.99.
SanBio Co has a quick ratio of 28.99. It generally indicates good short-term financial strength.
The historical rank and industry rank for SanBio Co's Quick Ratio or its related term are showing as below:
SNBIF'
s Quick Ratio Range Over the Past 10 Years
Min: 2.41 Med: 5.92 Max: 53
Current: 53
During the past 13 years, SanBio Co's highest Quick Ratio was 53.00. The lowest was 2.41. And the median was 5.92.
SNBIF's Quick Ratio is ranked better than 98.51% of 1409
companies
in the Biotechnology industry
Industry Median: 3.6
vs SNBIF: 53.00
SanBio Co (OTCPK:SNBIF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
SanBio Co Quick Ratio Related Terms
SanBio Co Quick Ratio Historical Data
* Premium members only.
The historical data trend for SanBio Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SanBio Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SanBio Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SanBio Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where SanBio Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
SanBio Co's Quick Ratio for the fiscal year that ended in Jan. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SanBio Co (SNBIF) has a Quick Ratio of 28.99 as of Jan. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SanBio Co and its competitors. This is 390% above median its historical median of 5.92. Over the past decade, SanBio Co's Quick Ratio has ranged from 2.41 to 53.00. According to the industry distribution chart, SanBio Co ranks #21 out of 1409 companies in the Biotechnology industry, placing it in the top 1.5%.
Is SanBio Co's Quick Ratio too high?
SanBio Co's current Quick Ratio of 28.99 is 390% above median its 10-year median of 5.92. Over the past 10 years, this metric has ranged from a low of 2.41 to a high of 53.00. The Biotechnology industry median Quick Ratio is 3.60. SanBio Co's value of 28.99 is 705.3% above this industry median. Based on the distribution chart, SanBio Co ranks #21 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SanBio Co ranks #21 out of 1409 companies for Quick Ratio. This places SanBio Co in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. SanBio Co's value of 28.99 is 705.3% above this benchmark. Historically, SanBio Co's own Quick Ratio has ranged from 2.41 to 53.00 over the past decade. While the company's 10-year median is 5.92 vs. the industry median of 3.60, SanBio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SanBio Co's current Quick Ratio of 28.99 is 705.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SanBio Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SanBio Co's current Quick Ratio is 28.99, which is 390% above median its own 10-year median of 5.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (SNBIF) has a current Quick Ratio of 28.99. The current Quick Ratio is 28.99, which is 390% above median its 10-year median of 5.92 and 705.3% above the Biotechnology industry median of 3.60. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For SanBio Co (SNBIF), the current Quick Ratio is 28.99 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score
Get the complete analysis for SNBIF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNBIF has been successfully added to your 
